RecruitingPhase 4NCT05042258
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Sponsor
Northwestern University
Enrollment
40 participants
Start Date
Aug 12, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old
Eligibility
Min Age: 6 YearsMax Age: 17 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Dupilumab for people with atopic dermatitis and sleep disturbance. The study is currently recruiting participants at 1 location. People eligible for this study include aged 6 Years to 17 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDupilumab
12 week dupilumab administration
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05042258
Related Trials
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
NCT072629831 location
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
NCT006058781 location
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT0639791116 locations
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
NCT065994111 location
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
NCT076458204 locations